<?xml version="1.0"?>
<?xml-stylesheet type="text/css" href="http://www.feuxdelamour.com/v4/skins/common/feed.css?303"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="fr">
		<id>http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=9_Worries_To_Ask_Around_PD0325901</id>
		<title>9 Worries To Ask Around PD0325901 - Historique des versions</title>
		<link rel="self" type="application/atom+xml" href="http://www.feuxdelamour.com/v4/index.php?action=history&amp;feed=atom&amp;title=9_Worries_To_Ask_Around_PD0325901"/>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=9_Worries_To_Ask_Around_PD0325901&amp;action=history"/>
		<updated>2026-04-07T17:52:18Z</updated>
		<subtitle>Historique pour cette page sur le wiki</subtitle>
		<generator>MediaWiki 1.20alpha</generator>

	<entry>
		<id>http://www.feuxdelamour.com/v4/index.php?title=9_Worries_To_Ask_Around_PD0325901&amp;diff=90231&amp;oldid=prev</id>
		<title>Brianoffice0 : Page créée avec « boulardii [http://www.selleckchem.com/products/PD-0325901.html MAPK inhibitor] treatment. The primary outcome was the incidence of diarrhea defined as the percentage of pa... »</title>
		<link rel="alternate" type="text/html" href="http://www.feuxdelamour.com/v4/index.php?title=9_Worries_To_Ask_Around_PD0325901&amp;diff=90231&amp;oldid=prev"/>
				<updated>2017-04-14T10:20:26Z</updated>
		
		<summary type="html">&lt;p&gt;Page créée avec « boulardii [http://www.selleckchem.com/products/PD-0325901.html MAPK inhibitor] treatment. The primary outcome was the incidence of diarrhea defined as the percentage of pa... »&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Nouvelle page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;boulardii [http://www.selleckchem.com/products/PD-0325901.html MAPK inhibitor] treatment. The primary outcome was the incidence of diarrhea defined as the percentage of patients developing a diarrhea. Diarrhea was defined as an increase in the frequency of bowel movements (&amp;gt;3/day) or decrease in stool consistency (Bristol stool scale 5 or 6). Secondary outcomes were: i) the onset of diarrhea, which was defined as the time between the inclusion of the patient and the onset of diarrhea; ii) the duration of diarrhea, which was defined as the number of days with diarrhea (the end of the diarrhea was defined as the moment when consistency (Bristol stool scale [http://en.wikipedia.org/wiki/GRB10 GRB10] 13C UBT. Table 1 Efficacy of Treatment and Severity of Diarrhea The sample size was calculated using the following formula N=Z2��[p��(1-P)]/E2=174 where N is the sample size, Z the confidence interval (=1.96), E the sampling error (=0.05) and P the incidence of AAD (=0.13). Data analysis was performed using SPSS 11.5 statistical software (Softonic; Softonic International S.A., http://en.softonic.com/s/spss-11.5-statistical-software-free-download). The onset time and duration of diarrhea were analyzed using two-tailed t-tests; p[http://www.selleckchem.com/products/epz-6438.html see more] while in the control group 26/92 (28.3%) patients had diarrhea (p the treatment group was 6.25��1.24 days, what was later than in the control group (4.05��1.11 days; p&lt;/div&gt;</summary>
		<author><name>Brianoffice0</name></author>	</entry>

	</feed>